Holen Sie sich die Stockscreener-App
1.18
1.67%
-0.02
Schlusskurs vom Vortag:
$1.20
Offen:
$1.22
24-Stunden-Volumen:
743.98K
Relative Volume:
0.50
Marktkapitalisierung:
$85.31M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.95M
KGV:
-1.3221
EPS:
-0.8925
Netto-Cashflow:
$-56.37M
1W Leistung:
-0.84%
1M Leistung:
-5.60%
6M Leistung:
-12.59%
1J Leistung:
-38.22%
1-Tages-Spanne:
$1.16
$1.2635
1-Wochen-Bereich:
$1.15
$1.2635
52-Wochen-Spanne:
$0.8719
$2.99
Biomea Fusion Inc Stock (BMEA) Company Profile
Firmenname
Biomea Fusion Inc
Sektor
Branche
Telefon
(650) 980-9099
Adresse
1599 INDUSTRIAL ROAD, SAN CARLOS
Compare BMEA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.18 | 85.31M | 0 | -44.95M | -56.37M | -0.8925 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2025-08-28 | Eingeleitet | Jefferies | Buy |
| 2025-06-03 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-10-09 | Eingeleitet | Edward Jones | Buy |
| 2024-09-27 | Hochstufung | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | Hochstufung | Truist | Hold → Buy |
| 2024-08-29 | Eingeleitet | CapitalOne | Overweight |
| 2024-06-11 | Herabstufung | Truist | Buy → Hold |
| 2024-06-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-04-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-06 | Eingeleitet | Truist | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-06-26 | Herabstufung | Jefferies | Buy → Hold |
| 2023-05-12 | Eingeleitet | Barclays | Overweight |
| 2023-03-29 | Bestätigt | Oppenheimer | Outperform |
| 2023-03-28 | Bestätigt | H.C. Wainwright | Buy |
| 2023-02-24 | Eingeleitet | Citigroup | Buy |
| 2022-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-01-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-11 | Eingeleitet | Jefferies | Buy |
| 2021-05-11 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Biomea Fusion Inc Aktie (BMEA) Neueste Nachrichten
Biomea Fusion Inc (BMEA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Biomea Fusion Inc (BMEA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Biomea Fusion Inc (BMEA) Institutional Confidence - TradingKey
Biomea Fusion Inc (BMEA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Biomea Fusion Inc (BMEA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Biomea Fusion Inc (BMEA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Team Fusion pinpoints this year leading trends at ADA2026 event - Traders Union
Biomea Fusion Inc (BMEA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Number of shareholders of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Biomea Fusion Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplineOne-Time Gain Impact - newsline.com
Biomea Fusion Inc. Q1 2026 Earnings: EPS Beat on Cost Discipline as Biotech Advances PipelinePost-Announcement Reaction - newsline.com
[Form 4] Biomea Fusion, Inc. Insider Trading Activity - Stock Titan
Biomea Fusion (BMEA) director granted 196,299 stock options at $1.15 exercise price - Stock Titan
Biomea Fusion (BMEA) director Ray Sumita granted 196,299 stock options - Stock Titan
Biomea Fusion (BMEA) director receives 173,711-share stock option grant at $1.15 - Stock Titan
Citi Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Biomea Fusion (NASDAQ: BMEA) details 2026 director and auditor votes - Stock Titan
BMEA: Directors and auditors were approved by majority vote, with results to be filed with the SEC - TradingView
BMEA: All proposals, including director elections and auditor ratification, were approved - TradingView
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Biomea Fusion, Inc. (BMEA) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow - Seeking Alpha
BMEA Q1 2026 Earnings: EPS Beat on Controlled Spending Overshadowed by Pipeline ConcernsAnalyst Drop Coverage - newsline.com
Biomea Fusion shows promising diabetes and obesity drug data, expands Phase I study for weight loss therapy. - Pluang
Biomea Fusion Presents Promising Clinical Data for Icovamenib and Expands Phase I Study of BMF-650 at ADA 2026 - Quiver Quantitative
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association ('ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study - The Manila Times
Biomea Fusion Says Icovamenib Data Show Muscle Preservation And Fat Reduction In Obesity And Diabetes - TradingView
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study - GlobeNewswire
BMEA: Phase II diabetes trials for a novel menin inhibitor target non-chronic, restorative therapy - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Biomea Fusion to study icovamenib with semaglutide for weight loss - Investing.com UK
Icovamenib GLP-1 therapy combination evaluated in Biomea Fusion academic study - Traders Union
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity - Investing News Network
Biomea Fusion to study icovamenib with semaglutide for weight loss By Investing.com - Investing.com South Africa
Biomea Fusion Announces Research Collaboration with - GlobeNewswire
Biomea Fusion icovamenib abstracts chosen for late-breaking poster presentations at diabetes conference - Traders Union
Biomea Fusion Q1 2026 Earnings: EPS Beats Estimates Despite No RevenueReturn On Assets - newsline.com
Biomea Fusion (BMEA) Holds Steady at $1.38, Testing Support as Traders Weigh Next MoveIsland Reversal - newsline.com
Biomea Fusion advances COVALENT-211 and COVALENT-212 research in type 2 diabetes - Traders Union
BMEA Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Progress in Clinical PipelineGuidance Accuracy Score - newsline.com
Biomea Fusion (BMEA) Stages a Rebound: Testing Key Resistance After a +3.65% GainDaily Profile - thelegaladvocate.com
Biomea Fusion Shares Surge Over 6% as BMEA Tests Key ResistanceRisk Reward Setups - newsline.com
Biomea Fusion Q1 2026 Earnings: Narrowed Loss per Share Exceeds Expectations as Pipeline Progress Drives Stock UptickEarnings Quality Score - thelegaladvocate.com
Biomea Fusion Q1 2026 Earnings: Narrower-Than-Expected Loss Fuels Positive Market ResponseEarnings Season Outlook - newsline.com
BMEA Stock Price, Quote & Chart | BIOMEA FUSION INC (NASDAQ:BMEA) - ChartMill
Biomea Fusion, Inc.Common Stock (NQ: BMEA - FinancialContent
Oppenheimer Keeps Their Buy Rating on Biomea Fusion (BMEA) - The Globe and Mail
Oppenheimer Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Raises Target Price to $7 - Moomoo
Biomea Fusion to Participate at Upcoming Investor Conferences - The Manila Times
Analyst Reiterates Buy on Biomea Fusion, Maintains $4 Price Target Amid Advancing Metabolic Pipeline - TipRanks
H.C. Wainwright Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Finanzdaten der Biomea Fusion Inc-Aktie (BMEA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):